Ameriprise’s Kalaris Therapeutics KLRS Stock Holding History

Ameriprise’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-466	Closed	-$23K	–	3997
2023 Q3	$23K	Buy	+466	New	+$31.8K	﹤0.01%	3863

Other funds holding KLRS

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Ameriprise's KLRS Position: Q4 2023 in Review

Ameriprise sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 466 shares — an estimated $23K sold.

Ameriprise first reported a position in KLRS in Q3 2023 and held it in 1 quarter. The position peaked at $23K in Q3 2023. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

Ameriprise reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
Ameriprise sold 466 Kalaris Therapeutics shares in Q4 2023, an estimated $23K.
Ameriprise first reported a position in Kalaris Therapeutics in Q3 2023 and held it in 1 quarter.
Ameriprise's Kalaris Therapeutics position peaked at $23K in Q3 2023.
81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Ameriprise's 13F filing for Q4 2023, filed 14 Feb 2024.